Landscape of G-quadruplex DNA structural regions in breast cancer

Robert Hänsel-Hertsch1,2,3,4, Angela Simeone4, Abigail Shea4

  • 1Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.

Nature Genetics
|August 5, 2020
PubMed

Insights

G-quadruplex (G4) DNA structures in breast cancer xenografts reveal subtypes and treatment sensitivity. Mapping G4 regions helps stratify tumors, uncovering heterogeneity and potential new therapeutic targets.

Area of Science:

  • Genomics
  • Cancer Biology
  • Structural Biology

Background:

  • Anticancer therapy response is limited by tumor heterogeneity.
  • G-quadruplex (G4) DNA structures are increasingly recognized for their role in cancer.

Purpose of the Study:

  • To map G-quadruplex (G4) DNA structure-forming regions (∆G4Rs) in breast cancer patient-derived tumor xenograft (PDTX) models.
  • To investigate the association of ∆G4Rs with gene expression, mutations, and breast cancer subtypes.
  • To explore the therapeutic potential of targeting G4 structures.

Main Methods:

  • Analysis of ∆G4R landscapes in 22 breast cancer PDTX models.
  • Correlation of ∆G4R distribution with gene promoters, somatic mutations, and transcription factor programs.
  • Stratification of PDTXs into G4-based subtypes and integrative clusters (ICs).
  • Assessment of G4-targeting small molecule sensitivity in PDTX cultures.

Main Results:

  • ∆G4Rs are linked to amplified gene promoters and somatic single-nucleotide variants.
  • G4 landscapes identified seven transcription factor programs and stratified PDTXs into at least three G4-based subtypes.
  • Most PDTXs exhibited multiple breast cancer subtypes (ICs), often with aggressive triple-negative IC10 gene activity.
  • PDTX models with higher ∆G4R levels showed increased sensitivity to G4-targeting drugs.

Conclusions:

  • G4 landscapes provide insights into intratumor heterogeneity in breast cancer PDTX models.
  • G4-based stratification improves breast cancer classification and identifies potential therapeutic vulnerabilities.
  • Targeting G4 DNA represents a promising strategy for novel breast cancer treatments.